Human Carbonic Anhydrase II as Host Protein for the Creation of Artificial Metalloenzymes : the Asymmetric Transfer Hydrogenation of Imines by Monnard, Fabien W. et al.
Chemical Science
EDGE ARTICLE
Pu
bl
ish
ed
 o
n 
12
 Ju
ne
 2
01
3.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t B
as
el
 o
n 
10
/0
4/
20
17
 1
4:
42
:3
1.
 
View Article Online
View Journal  | View IssueFig. 1 Artiﬁcial transfer hydrogenase for
bearing bidentate ligand (green) ensure
human carbonic anhydrase II (blue). Varia
with genetic modiﬁcation of the host prot
of the catalyst's performance for the synt
aDepartment of Chemistry, University of B
Switzerland. E-mail: thomas.ward@unibas.
267 10 04
bBiozentrum, University of Basel, Kling
Switzerland. E-mail: tilman.schirmer@unib
61 267 20 89
† Electronic supplementary information (
expression of hCA II in E. Coli. Detaile
Synthesis and characterization of
10.1039/c3sc51065d
Cite this: Chem. Sci., 2013, 4, 3269
Received 22nd April 2013
Accepted 31st May 2013
DOI: 10.1039/c3sc51065d
www.rsc.org/chemicalscience
This journal is ª The Royal Society ofHuman carbonic anhydrase II as host protein for the
creation of artiﬁcial metalloenzymes: the asymmetric
transfer hydrogenation of imines†
Fabien W. Monnard,a Elisa S. Nogueira,a Tillmann Heinisch,ab Tilman Schirmerb
and Thomas R. Ward*a
In the presence of human carbonic anhydrase II, aryl-sulfonamide-bearing IrCp* pianostool complexes
catalyze the asymmetric transfer hydrogenation of imines. Critical cofactor–protein interactions revealed
by the X-ray structure of [(h5-Cp*)Ir(pico 4)Cl] 9 3 WT hCA II were genetically optimized to improve the
catalytic performance of the artiﬁcial metalloenzyme (68% ee, kcat/KM 6.11  103 min1 mM1).1 Introduction
Articial metalloenzymes result from the incorporation of an
organometallic moiety within a protein scaﬀold. In this context,
three anchoring strategies have been pursued: covalent, supra-
molecular and dative.1–17 In the context of dative anchoring
strategies, we hypothesized that human Carbonic Anhydrase II
(hCA II hereaer) may provide a suitable scaﬀold for the crea-
tion of articial metalloenzymes. Indeed, para-substituted aryl-imine reduction. An aryl-sulfonamide-
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tion of the bidentate ligand combined
ein allows a chemogenetic optimization
hesis of salsolidine.
asel, Spitalstrasse 51, CH-4056 Basel,
ch; Fax: +41 61 267 10 05; Tel: +41 61
elbergstrasse 50/70, CH-4056 Basel,
as.ch; Fax: +41 61 267 21 09; Tel: +41
ESI) available: Modied protocol for the
d description of the X-ray structure.
all new compounds. See DOI:
Chemistry 2013sulfonamides display high aﬃnity for the catalytic Zn ion which
lies at the bottom of a deep hydrophobic funnel-shaped cavity.
We thus speculated that upon tethering an aryl-sulfonamide to a
bidentate ligandmay allow to anchor an organometallic catalyst
within hCA II.18 This was recently conrmed with an X-ray
structure of an aryl-sulfonamide-bearing Ru pianostool complex
incorporated within hCA II.19,20 However, this latter proved
catalytically inactive for a variety of transformations. Herein we
report on our eﬀorts to create an articial transfer hydrogenase
based on the incorporation of a catalytically active iridium pia-
nostool complex within hCA II, Fig. 1.
2 Results and discussion
2.1 Ligand synthesis
With the aim of identifying the most suitable scaﬀold for
incorporation within hCA II, we set out to synthesize diﬀerent
ligands bearing a p-aryl-sulfonamide anchor. As previously
demonstrated, the {IrCp*}2+ moiety has proven superior to its
{RhCp*}2+ and {Ru(arene)}2+ congeners for the reduction of
imines in water.21,22 The synthesis of bis-pyridine 1, bipyridine
2, amino-pyridine 3 and sulfonamido-pyridine 4 and 5 ligands
and the corresponding complexes 6–10 is presented in Schemes
1 and 2 (see ESI† for full experimental details).
The synthesis of bis-pyridine 1 was reported in 2011.19 The
preparation of bipy 2 started with an aldol condensation reac-
tion between 4-(methylthio)benzaldehyde 11 and 2-acetylpyr-
idine 12, to aﬀord the corresponding phenyl-substituted-
bipyridine 13.23 The sulfonamide anchor was installed in three
steps via oxidation of the thiomethyl function,24 which was
converted to the sulfonamide using the method disclosed by
Zhang et al.25 The sulfonamide-bearing bipyridine ligand 2 was
obtained in 8% overall yield, Scheme 1.
The synthesis of 2-picolylamine-bearing ligand 3 relied on a
palladium-catalyzed cross-coupling strategy as key step.
Commercially available chloropyridine 14 and aryl-sulfonamideChem. Sci., 2013, 4, 3269–3274 | 3269
Scheme 1 Synthesis of pianostool complexes 6 and 7 bearing bis-pyridine-type
bidentate ligands. Reagents and conditions: (a) [Cp*IrCl2]2, H3CCN, reﬂux, 4 h; (b)
NaOH aq./MeOH, RT; (c) ethyl vinyl ether, 4 A˚ molecular sieves, THF, RT; (d)
H2NO$HCl, H3CCN, reﬂux; (e) KMnO4/MnO2, CH2Cl2, RT; (f) (i) DIPA, n-BuLi, THF,
0 C, (ii) trimethylsilyl chloride, RT; (g) (i) TBAF,THF, reﬂux, (ii) hydroxylamine-O-
sulfonic acid, H2O, RT.
Scheme 2 Synthesis of pianostool complexes 8–10 bearing picolylamine-type
bidentate ligands. Reagents and conditions: (a) Pd(PPh3)4, Na2CO3, THF, 80 C; (b)
LiAlH4$AlCl3, THF, RT; (c) TFA, RT; (d) [Cp*IrCl2]2, EtOH, reﬂux; (e)m-CPBA, CH2Cl2,
RT; (f) TFAA, CH2Cl2, 0 C; (g) MnO2, CH3Cl, reﬂux; (h) H2NO$HCl, NaHCO3, MeOH,
RT; (i) TFA, Zn, 0 C; (j) arylsulfonylchloride, DIPEA, RT; (k) Pd(PPh3)4, Na2CO3, H2O/
dioxane, microwave, 150 C.
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View Article Online15 were coupled under Suzuki conditions. Reduction of the
nitrile with (AlCl3)$LiAlH4, followed by deprotection with TFA
aﬀorded the corresponding ligand 3 in 40% overall yield.26,27
For the synthesis of ligands pico 4–H and pico 5–H, the
oxime 17 was identied as advanced intermediate, easily
accessed on large scale from commercially available 4-bromo-2-
methylpyridine 16. Its synthesis was based on key steps starting
from a Boekelheide reaction28,29 and followed by an oxidation to
the corresponding aldehyde.30 Treatment with hydroxylamine
hydrochloride yielded the oxime 17. Reduction by Zn in tri-
uoroacetic acid31 followed by treatment with an aryl-sulfonyl-
chloride derivative yielded the sulfonamide-pyridines 18 and
19, respectively.32 Finally, the benzene sulfonamide anchor was
introduced via Suzuki cross-coupling reaction to aﬀord the
bidentate ligands pico 4–H and pico 5–H in 5% overall yield.33
The aminosulfonamide-bearing ligands 1–5 were reacted
with [Cp*IrCl2]2 to aﬀord the corresponding mononuclear pia-
nostool complexes [(h5-Cp*)Ir(bispy 1)Cl]+ 6, [(h5-Cp*)Ir(bipy 2)-
Cl]+ 7 and [(h5-Cp*)Ir(pico 3)Cl]+ 8, [(h5-Cp*)Ir (pico 4)Cl] 9 and
[(h5-Cp*)Ir(pico 5)Cl] 10 respectively. These were puried by
precipitation in acetonitrile or CH2Cl2 to aﬀord analytically pure
aryl-sulfonamide-bearing iridium pianostool complexes for
anchoring within hCA II, Schemes 1 and 2.3270 | Chem. Sci., 2013, 4, 3269–32742.2 Catalysis results
In order to evaluate the transfer hydrogenase activity of the
pianostool complexes 6–10, the salsolidine precursor was
selected as prochiral imine.34 The sulfonamide-bearing catalysts
6–10 (1.8 mol% vs. imine, 5% DMSO in MOPS buﬀer, pH 7.5,
40 C, 20 hours, 150 eq. HCO2Na) were tested both in the
absence and in the presence of hCA II (see ESI† for experimental
details). From these data, it appears that both bispy- and bipy-
bearing complexes [(h5-Cp*)Ir(bispy 1)Cl]+ 6 and [(h5-Cp*)-
Ir(bipy 2)Cl]+ 7 are very poor transfer hydrogenation catalysts
(Table 1, entries 1–4). In contrast, the complex bearing theThis journal is ª The Royal Society of Chemistry 2013
Table 1 Selected results for the chemogenetic optimization of artiﬁcial transfer
hydrogenases for the production of salsolidinea at 40 C
Entry Complex hCA II Conv. % ee %
1 6 — 3 n.d.
2 6 WT 0 n.d.
3 7 — 14 n.d.
4 7 WT 0 n.d.
5 8 — Quant. Rac.
6 8 WT 20 5 (S)
7 8 I91A 46 1 (S)
8 8 K170A 34 3 (S)
9 9 — 81 1 (S)
10 9 WT 69 32 (S)
11 9 I91A 67 29 (S)
12 9 K170A 40 30 (S)
13 10 — 86 2 (R)
14 10 WT 51 30 (S)
15 10 I91A 58 5 (R)
16 10 K170A 25 14 (S)
a The reaction was carried out for 20 h at 40 C with 0.35 mM complex
(nal concentration, 1.8 mol% vs. substrate), 0.4 mM hCA II in MOPS
buﬀer (0.4 M, pH 7.5, 200 mL containing 5% DMSO), 20 mM imine
substrate and 3 M formate. The yield and ee is an average of at least
two catalytic runs d ee: 1%, d conv.: 4%.
Table 2 Selected results for the chemogenetic optimization of artiﬁcial transfer
hydrogenases for the production of salsolidinea at 4 C
Entry Complex hCA II Conv. % ee %
1 8 — 78 Rac.
2 8 WT 7 9 (S)
3 8 I91A 9 2 (R)
4 8 K170A 8 3 (R)
5 9 — 7 Rac.
6 9 WT 27 68 (S)
7 9 I91A 23 64 (S)
8 9 K170A 21 67 (S)
9 9b WT 82 70 (S)
10 9b I91A 70 66 (S)
11 9b K170A 57 68 (S)
12 10 — 10 2 (R)
13 10 WT 7 40 (S)
14 10 I91A 9 15 (S)
15 10 K170A 6 16 (S)
a Reactions were carried out for 44 h at 4 C with 0.35mM complex (nal
concentration), 20 mM substrate, 0.4 mM protein, MOPS buﬀer (0.4 M,
pH 7.5, 200 mL, 5% DMSO) and 3 M formate. b Reactions were carried
out for 44 h at 4 C with 0.35 mM complex (nal concentration), 4
mM substrate, 0.4 mM protein, MOPS buﬀer (0.4 M, pH 7.5, 200 mL,
5% DMSO) and 3 M formate. The yield and ee is an average of at least
two catalytic runs d ee: 2%, d conv.: 5%.
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View Article Onlineamino-pyridine ligand [(h5-Cp*)Ir(pico 3)Cl]+ 8 performed well
in the absence of hCA II (>55 turnover numbers, TON). Disap-
pointingly, incorporation within hCA II lead to a signicant
erosion of its catalytic performance (TON 11, ee 5% (S), Table 1,
entries 5 and 6). A recent report by Çetinkaya suggests that the
transfer hydrogenase activity of d6-pianostool complexes with a
sulfonamide-bearing 2-picolylamine is superior to that of the
corresponding the 2-picolylamine-containing catalyst.35 We
thus set out to synthesize and evaluate the activity of [(h5-Cp*)-
Ir(pico 4)Cl] 9. Although less active than [(h5-Cp*)Ir(pico 3)Cl]+ 8
in the absence of host protein (45 vs. >55 TONs), incorporation
within hCA II yielded salsolidine in 69% yield and 32% ee (S)
(Table 1, entries 9 and 10). Inspired by Carreira's observation
that uorination of the aryl-moiety of amino-sulfonamide
ligands leads to improved transfer hydrogenase activity in
water, we tested the diuorinated catalyst [(h5-Cp*)Ir(pico 5)Cl]
10.36 Unfortunately, its catalytic performance remained modest
both in the absence and within hCA II (Table 1, entries 13–16).
These results highlight the critical inuence of the second
coordination sphere interactions on the catalytic performance
of pianostool complexes with a well dened rst coordination
sphere.
With the aim of identifying critical residues in the most
promising ATHase based on WT hCA II, the X-ray structure of
[(h5-Cp*)Ir(pico 4)Cl] 93 hCA II was determined (vide infra, see
Fig. 3). The structure revealed the proximity of residues I91 and
K170 to the articial cofactor, lining the hemisphere potentially
occupied by the substrate. With the aim of tailoring more space
for the substrate binding pocket, hCA II single mutants I91A
and K170A were produced, puried and tested as host protein
(see ESI† for details).
As for WT hCA II, both ATHase mutants [(h5-Cp*)Ir(pico 4)-
Cl] 9 3 I91A and [(h5-Cp*)Ir(pico 4)Cl] 9 3 K170A displayedThis journal is ª The Royal Society of Chemistry 2013good TONs and similar ees at 40 C (Table 1, entries 11 and 12).
Upon decreasing the temperature to 4 C, the bare catalyst [(h5-
Cp*)Ir(pico 4)Cl] 9 showed low ATHase activity (Table 2, entry 5).
In contrast, both [(h5-Cp*)Ir(pico 4)Cl] 93WT hCA II and [(h5-
Cp*)Ir(pico 4)Cl] 9 3 I91A aﬀorded salsolidine with signi-
cantly improved selectivity at 4 C (68% ee (S), 27% conv. and
64% ee (S), 23% conv. respectively). Upon increasing the catalyst
loading to 9%, the conversions could be upgraded to 82% and
70% respectively aer 44 hours (Table 2, entries 9 and 10).
2.3 Kinetic- and thermodynamic characterization
Para-substituted aryl-sulfonamides are widely studied inhibi-
tors for hCA II and their aﬃnities vary over several orders of
magnitude.18 In order to ensure that, under catalytic conditions
(i.e. [hCA II] ¼ 0.4 mM; [complex] ¼ 0.35 mM), the bulky pia-
nostool complexes were quantitatively incorporated within hCA
II, their aﬃnity towards hCA II was determined (see ESI† for
details).19,37–41 It is interesting to note that the sulfonamide-
bearing pianostool complexes [(h5-Cp*)Ir(pico 4)Cl] 9 and [(h5-
Cp*)Ir(pico 5)Cl] 10 displayed signicantly higher aﬃnity
towards hCA II compared to the picolylamine complex [(h5-Cp*)-
Ir(pico 3)Cl]+ 8 (compare 15 nM and 17 nM for complexes 9 and
10 respectively to 1280 nM for complex 8, Table 3, entries 3–5).
This suggests that a secondary hydrophobic contact between
the additional aryl group of the ligand and the hydrophobic
funnel-shaped hCA II active site contributes to signicantly
increase the aﬃnity of these complexes.42
Having ensured that the pianostool complexes are indeed
quantitatively incorporated within hCA II under catalytic
conditions, the saturation kinetics behavior of [(h5-Cp*)Ir(pico
4)Cl] 9, [(h5-Cp*)Ir(pico 4)Cl] 9 3 WT hCA II and [(h5-Cp*)-
Ir(pico 4)Cl] 9 3 I91A hCA II was determined, Fig. 2. UponChem. Sci., 2013, 4, 3269–3274 | 3271
Table 3 Summary of aﬃnity constants for sulfonamide-bearing pianostool
complexes 6–10 towards WT hCA II
Entry Complex Kd/nM
1 6a 120  20
2 7a 270  40
3 8a 1280  200
4 9b 15  2
5 10a 17  8
a Aﬃnity determined using the rate of hydrolysis of p-
nitrophenylacetate. b Aﬃnity determined using competition with
dansylamide (see ESI for experimental details).
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View Article Onlinevarying the imine concentration and determining by HPLC the
initial rate of salsolidine formation, very diﬀerent kinetic
proles were obtained, Fig. 2. For the bare catalyst [(h5-Cp*)-
Ir(pico 4)Cl] 9, the reaction rate was essentially independent of
the imine concentration at [imine] > 1.17 mM. Unfortunately,
lowering the imine concentration below 1.17 mM (i.e. less than
three eq. vs. [(h5-Cp*)Ir(pico 4)Cl] 9) renders the pseudo rst
order kinetics approximation invalid and thus precludes the
precise determination of kcat for the reaction in the absence of
hCA II. Two possibilities may be put forward to explain the
behaviour of the free cofactor [(h5-Cp*)Ir(pico 4)Cl] 9: (i) KM <
1.17 mM or (ii) the substrate is not involved in the rate deter-
mining step.
In stark contrast, upon incorporation within hCA II iso-
forms, saturation kinetic proles were observed. For [(h5-Cp*)-
Ir(pico 4)Cl] 9 3 WT hCA II, severe substrate inhibition was
observed (Ki 45 mM). A single point mutation with [(h
5-Cp*)-
Ir(pico 4)Cl] 93 I91A hCA II removed the substrate inhibition.
(kcat/KM: 9.9  103 min1 mM1 vs. 6.1  103 min1 mM1
for [(h5-Cp*)Ir(pico 4)Cl] 93WT hCA II and [(h5-Cp*)Ir(pico 4)-
Cl] 9 3 I91A hCA II, respectively, Fig. 2.) Comparing the satu-
ration kinetics behavior of the articial metalloenzyme with
that of the organometallic catalyst demonstrates that the hostFig. 2 Kinetic proﬁles of [(h5-Cp*)Ir(pico 4)Cl]+ 9 (red), [(h5-Cp*)Ir(pico 4)Cl]+ 9
3WT hCA II (black trace: KM 6.67  2.20 mM, Ki 45  15 mM, kcat 6.60  102 
1.17  102 min1) and [(h5-Cp*)Ir(pico 4)Cl]+ 9 3 I91A hCA II (blue trace: KM
8.63  1.30 mM, kcat 5.28  102  0.23  102 min1).
3272 | Chem. Sci., 2013, 4, 3269–3274protein has a major impact on the respective kinetic proles of
the three catalysts.
2.4 X-ray structure of the hCA II metalloenzyme
To gain structural insight on the ATHase [(h5-Cp*)Ir(pico 4)Cl] 9
3 hCA II, diﬀraction data were collected to 1.3 A˚ resolution of a
hCA II crystal aer soaking in a solution of complex 9. Upon
solving the crystal structure, residual density was apparent in
the funnel-shaped active site of hCA II in close proximity to the
catalytic zinc (Fig. 3). The pyridine and terminal benzene-
sulfonamide moieties of complex 9 were modeled into the
density with the sulfonamide forming a coordinative bond with
the catalytic zinc and the benzene and pyridine ring arranged
virtually coplanarly. A strong peak in both the Fo–Fc and the
anomalous diﬀerence density map (23s and 8s, respectively)
indicated the presence of the Ir atom in close proximity to the
pyridine. The atom, however, is not fully occupied as found
upon renement, which yielded 30% occupancy. The low
occupancy may be due to partial dissociation of the metal upon
complex binding to the protein. The iridium is coordinated by
the pyridine nitrogen and the nitrogen of the secondary ben-
zenesulfonamide. Consistent with the low occupancy, no elec-
tron density was observed for the Cp* ring, the chlorine, and the
secondary benzenesulfonamide. In the nal model of the fully
coordinated Ir atom the occupancy of these groups was set to
30%. Upon renement no negative density emerged in the Fo–Fc
map. The pianostool moiety of the complex 9 is located in an
hydrophobic groove formed by residues F131, V135, L198, P202
and L204.Fig. 3 Close-up view of the active site in the crystal structure of complex 9 3
hCA II (PDB code 3ZP9). Complex 9 is depicted in stick representation. The protein
is represented in surface representation with oxygens and nitrogens in red and
blue color, respectively. Residues of the hydrophobic wall (P131, V135, P202,
L204) and those that were chosen for genetic optimization (I91, K170) are
highlighted through the surface as stick representation. The occupancies of the
{IrCp*Cl}+ fragment and the secondary benzenesulfonamide in the eclipsed-
conformation are 30%. The salsolidine precursor (orange) was qualitatively
modeled in the active site to yield the observed (S)-enantiomer of the product.
The electron density of the Fo–Fc omit map (grey color) and the anomalous
diﬀerence density (green color) are contoured at 3s and 4s, respectively.
This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineResidual density in the Fo–Fc omit map was encountered in
proximity to the secondary benzenesulfonamide. Rotation of
this group around the Npy–C–C–N bond by 135 positions the
sulfur atom in this density. Thus, upon dissociation of the
iridium, the secondary benzenesulfonamide may undergo a
conformational change from an eclipsed- to an anticlinal-
conformation. This would account for up to 70% of the total
occupancy of the ligand (ESI Fig. S6†). In both, the eclipsed- and
the anticlinal-conformation, the aromatic ring of the secondary
benzenesulfonamide group is located in proximity to the side
chains of E69, D72, I91 and F131.
A qualitative model of the ATHase 9 3 hCA II in complex
with the salsolidine precursor was constructed based on the
structural and the functional data (Fig. 3). The substrate
binding site is constituted by complex 9 and residues H4, L60,
N62, H64, K170 and G171, which, thus, are target amino acids
for future genetic optimization of the ATHase (ESI Fig. S7†).
It is conceivable that the reduction of the side-chain-size in
the I91Amutant changes the relative position of the substrate to
the cofactor. However, it is not obvious from the X-ray structure
how this abrogates the observed substrate inhibition.3 Outlook
With the aim of creating articial transfer hydrogenases based
on hCA II as protein scaﬀold, ve IrCp*-complexes bearing N^N
bidentate ligands were screened. While the bare catalyst proved
only moderately active, upon incorporation in hCA II, complex
[(h5-Cp*)Ir(pico 4)Cl] 9 displayed signicantly improved cata-
lytic performance both in terms of activity and selectivity at 4 C
(up to 68% ee). Saturation kinetic analysis of the WT ATHase
revealed however severe substrate inhibition. Guided by the X-
ray structure of complex [(h5-Cp*)Ir(pico 4)Cl] 9 3 WT hCA II,
the catalytic site was expanded by mutation of close-lying
isoleucine 91 into an alanine. This chemogenetically optimized
ATHase [(h5-Cp*)Ir(pico 4)Cl] 9 3 I91A hCA II no longer
suﬀered from substrate inhibition and displayed signicant
rate enhancement over the organometallic catalyst. Current
eﬀorts are aimed at further engineering the catalytic site by
genetic introduction of additional substrate recognition
elements.Acknowledgements
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